HNRNPH2

Across TCGA pan-cancer cohorts, HNRNPH2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of HNRNPH2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HNRNPH2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types HNRNPH2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where HNRNPH2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HNRNPH2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.306	<.001	12	view →
HNSC	All	III,IV	+0.141	<.001	11	view →
COAD	Female	II,III,IV	+0.235	<.001	9	view →
LUAD	Female	All	+0.252	<.001	8	view →
LSCC	Male	II,III,IV	+0.099	<.001	4	view →
OV	All	All	+0.202	.023	2	view →
PDAC	All	All	+0.098	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

HNRNPH2–CCRCC

Open the CCRCC breakdown →